The company is committed to expanding its operations in the U.S. to enhance and diversify its in-house drug discovery, preclinical research, and translational capabilities to further complement its proprietary platforms and early-stage pipeline, it said. Gracell chose to establish its innovation center in the Cornerstone Research Center in San Diego.

The new hub includes a state-of-the-art laboratory, along with office space. In addition, Gracell announced it is expanding its R&D team in the San Diego area.

Gracell, FutureGen to develop engineered immunotherapies
Gracell Biotechnologies has signed an exclusive licensing agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin...

Gracell advances study, signs cell therapy deal
Gracell Biotechnologies has moved ahead with a cancer treatment research study and has signed a deal to manufacture its cell therapy products.

Gracell secures funding to advance CAR T therapies
Gracell Biotechnologies has secured $100 million in series C funding to expand its chimeric antigen receptor (CAR) T-cell therapies.